Glioblastoma
April 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Glioblastoma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Glioblastoma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Glioblastoma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Glioblastoma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Current and emerging EGFR therapies for glioblastoma.
Authors:Artene SA, Tuta C, Dragoi A, Alexandru O, Stefana Oana P, Tache DE, Danciulescu MM, Boldeanu MV, Silosi CA, Dricu A
Institution:a Department of Functional Sciences , University of Medicine and Pharmacy of Craiova, Craiova, Romania. Craiova, Craiova, Romania. Craiova, Craiova, Romania. Carol Davila, Bucharest, Romania. Craiova, Craiova, Romania. Craiova, Craiova, Romania. Craiova, Romania. Craiova, Romania. Pharmacy of Craiova, Craiova, Romania. Craiova, Craiova, Romania.
Journal:J Immunoassay Immunochem. 2018;39(1):1-11. doi: 10.1080/15321819.2017.1411816. Epub 2018 Feb 2.

2:Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Authors:Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z
Institution:Lou and Jean MalnatiBrain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine, Chicago, Illinois. Switzerland. 1127, Institut du Cerveau et de la Moelle epiniere, ICM, F-75013, Paris, France. Switzerland. 1127, Institut du Cerveau et de la Moelle epiniere, ICM, F-75013, Paris, France. Switzerland. Medicine, Bundang, Korea. Switzerland.
Journal:JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718.

3:Lomustine and Bevacizumab in Progressive Glioblastoma.
Authors:Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ
Institution:From the University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B., M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.); Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris, Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R., F.D.) - all in France; and the Departments of Oncology and Neurology, University Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
Journal:N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.

4:Targeting the perivascular niche in brain tumors.
Authors:Seano G
Institution:Institut Curie, PSL Research University.
Journal:Curr Opin Oncol. 2018 Jan;30(1):54-60. doi: 10.1097/CCO.0000000000000417.

5:Results of a Policy of Fast Tapering of Steroids After Resection Surgery in Glioblastoma.
Authors:Diez Valle R, Becerra Castro V, Marigil Sanchez M, Gallego Perez-Larraya J, Nunez-Cordoba JM, Tejada Solis S
Institution:Department of Neurosurgery, University Clinic of Navarra, Pamplona, Spain. Electronic address: rdiezvalle@unav.es. Navarra, Pamplona, Spain.
Journal:World Neurosurg. 2018 Jan;109:e845-e852. doi: 10.1016/j.wneu.2017.10.110. Epub 2017 Oct 28.

6:Pseudoprogression as an adverse event of glioblastoma therapy.
Authors:Balana C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-Garcia M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villa S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F
Institution:Medical Oncology, Institut Catala Oncologia (ICO), Badalona, Barcelona, Spain. Research Institute (IDIBGI), Hospital Universitari Dr Josep Trueta, Girona, Spain. LLobregat, Barcelona, Spain. Barcelona, Spain. LLobregat, Barcelona, Spain.
Journal:Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3.

7:Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Authors:Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M
Institution:Sidney Kimmel Cancer Center and Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. Illinois. Philadelphia, Pennsylvania. Foundation, Phoenix, Arizona. Illinois; NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. Philadelphia, Pennsylvania. Electronic address: maria.werner-wasik@jefferson.edu.
Journal:Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

8:A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma: A systematic review and meta-analysis.
Authors:Wang Z, Yang G, Zhang YY, Yao Y, Dong LH
Institution:aDepartment of Radiotherapy, Norman Bethune First Hospital bDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
Journal:Medicine (Baltimore). 2017 Nov;96(44):e8444. doi: 10.1097/MD.0000000000008444.

9:Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Authors:van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA
Institution:Brain Tumor Center, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl. University Medical Center, New York, NY, USA. Francisco, CA, USA. Royal Brisbane and Women's Hospital, Brisbane, Australia.
Journal:Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

10:Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival.
Authors:Delgado-Fernandez J, Garcia-Pallero MA, Blasco G, Penanes JR, Gil-Simoes R, Pulido P, Sola RG
Institution:Division of Neurosurgery, University Hospital La Princesa, Madrid, Spain. Electronic address: juan.delgado.fdez@gmail.com.
Journal:World Neurosurg. 2017 Dec;108:610-617. doi: 10.1016/j.wneu.2017.09.062. Epub 2017 Sep 20.

11:Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Authors:Scoccianti S, Krengli M, Marrazzo L, Magrini SM, Detti B, Fusco V, Pirtoli L, Doino D, Fiorentino A, Masini L, Greto D, Buglione M, Rubino G, Lonardi F, Migliaccio F, Marzano S, Santoni R, Ricardi U, Livi L
Institution:Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. silvia.scoccianti@unifi.it. Orientale, Novara, Italy. Brescia, Italy. Italy. Orientale, Novara, Italy. Italy. Brescia, Italy. Italy.
Journal:Radiol Med. 2018 Jan;123(1):48-62. doi: 10.1007/s11547-017-0806-y. Epub 2017 Sep 6.

12:Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Authors:Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A
Institution:Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. York. York. York. Francisco, California. York. York; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. York, New York. York, New York. York. York, New York. York. York. York, New York. York. Electronic address: aomuro@med.miami.edu.
Journal:Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804. doi: 10.1016/j.ijrobp.2017.06.2466. Epub 2017 Jun 30.

13:Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site.
Authors:Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J
Institution:McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: avishek.chatterjee@mail.mcgill.ca.
Journal:Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.

14:Biomarkers and therapeutic advances in glioblastoma multiforme.
Authors:Sasmita AO, Wong YP, Ling APK
Institution:Division of Applied Biomedical Sciences & Biotechnology, School of Health Sciences, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia.
Journal:Asia Pac J Clin Oncol. 2018 Feb;14(1):40-51. doi: 10.1111/ajco.12756. Epub 2017 Aug 25.

15:The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma.
Authors:Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, Preusser M, Widhalm G, Kiesel B, Lutgendorf-Caucig C, Dieckmann K, Steffal C, Marosi C, Hassler MR
Institution:Department of Medicine I, Medical University of Vienna, Comprehensive Cancer Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria; Institute of Radiation Oncology, Kaiser-Franz-Josef Hospital, Vienna, Austria; MedAustron Ion Therapy Center, Wiener Neustadt, Austria. Austria. Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria. christine.marosi@meduniwien.ac.at. Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria; Sonnberghof, Bad Sauerbrunn, Austria.
Journal:Radiother Oncol. 2017 Nov;125(2):228-233. doi: 10.1016/j.radonc.2017.07.027. Epub 2017 Aug 8.

16:Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Authors:Malmstrom A, Poulsen HS, Gronberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Lysiak M, Dowsett J, Kristensen BW, Soderkvist P, Rosell J, Henriksson R
Institution:a Department of Oncology , Linkoping University Hospital , Linkoping , Sweden. Linkoping , Sweden. University of Science and Technology , Trondheim , Norway. Trondheim , Norway. Denmark , Odense , Denmark. Sweden. Linkoping , Sweden. Linkoping , Sweden. Research, University of Southern Denmark , Odense C , Denmark. Research, University of Southern Denmark , Odense C , Denmark. Linkoping , Sweden. Linkoping , Sweden.
Journal:Acta Oncol. 2017 Dec;56(12):1776-1785. doi: 10.1080/0284186X.2017.1332780. Epub 2017 Jul 4.

17:Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Authors:Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE
Institution:Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universitat Munchen (TUM), Ismaninger Strasse 22, 81675, Munchen, Germany. Christoph.Straube@mri.tum.de. Universitat Munchen (TUM), Ismaninger Strasse 22, 81675, Munchen, Germany. Munchen (TUM), Munchen, Germany. Munchen (TUM), Munchen, Germany. Munchen (TUM), Munchen, Germany. Munchen (TUM), Munchen, Germany. (TUM), Munchen, Germany. Munchen (TUM), Munchen, Germany. Universitat Munchen (TUM), Ismaninger Strasse 22, 81675, Munchen, Germany. (DRS), Helmholtz Zentrum Munchen, Ingolstadter Landstrasse 1, 85764, Oberschleissheim, Germany.
Journal:Strahlenther Onkol. 2017 Nov;193(11):897-909. doi: 10.1007/s00066-017-1161-6. Epub 2017 Jun 14.

For a FREE PREVIEW of the Medifocus Guidebook on Glioblastoma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Glioblastoma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Glioblastoma...
at a Special 20% Discount


Medifocus Guidebook on Glioblastoma

Updated: January 15, 2018
164 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Glioblastoma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

GL93043975

Coupon Expires: July 18, 2018



What Our Customers Are Saying...

"To be diagnosed with a glioblastoma is devastating news. The MediFocus Guidebook on Glioblastoma clearly explained medical terms and adopted a positive approach although not discounting the problems."
E.S.
London, England


"Your Guidebook was EXTREMELY helpful and full of valuable information. I was able to understand "doctor language" and sound educated myself. It was well worth the price."
D.S.
Fairview, Tennessee


"I had never heard of Glioblastoma until one of my relatives was diagnosed with it and was given a very pessimistic outlook. Your Guidebook provided me with the background and sources of additional information necessary to allow me to be of help to him as he decided on his treatment options."
R.W.R.
Pittsfield, Massachusetts



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.